MedTrace Logo

Evaluating an Alternative Clinical Genetics Cancer Care Deliver Model

NCT03934606 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1488

Last updated 2025-04-10

No results posted yet for this study

Summary

To evaluate an alternative clinical genetics cancer care delivery model, using non-genetic providers to introduce and order genetic testing. 250 prostate and 250 pancreatic patients will be recruiting. They will undergo genetic testing and complete study questionnaires. Results from this pilot study will be used to inform the strategies used by the Clinical Risk Evaluation Program (CREP) Genetic Counelors (CGS) and GI/GU physicians to deliver genetic testing and return genetic risk information to patients with prostate or pancreatic cancer.

Conditions

  • Pancreas Cancer
  • Prostate Cancer
  • Hereditary Cancer
  • Genetic Predisposition to Disease

Interventions

BEHAVIORAL

Genetic testing for hereditary predisposition

Change in distress levels (HADS-Anxiety) from Baseline to Assessments #2 and #3, measured as an effect size among participants who receive a pathogenic variant(s), no pathogenic variant(s), and variant(s) of uncertain significance

Sponsors & Collaborators

  • Abramson Cancer Center at Penn Medicine

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2025-01-31
Completion
2025-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03934606 on ClinicalTrials.gov